Yoshiyuki Yamaura
Overview
Explore the profile of Yoshiyuki Yamaura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koishikawa T, Fujiwara K, Taskar K, Zamek-Gliszczynski M, Yoshida K, Chu X, et al.
Clin Pharmacol Ther
. 2024 Nov;
117(2):523-533.
PMID: 39497599
This study was designed to assess the quantitative performance of endogenous drug-drug interaction (DDI) biomarkers (N1-methylnicotinamide (1-NMN), N1-methyladenosine (mA), and creatinine) for the organic cation transporters, OCT2 and MATE1/2K in...
2.
Kono K, Nunoya K, Nakamura Y, Bi J, Mukunoki A, Takeo T, et al.
Mol Pharm
. 2022 Jul;
19(9):3450.
PMID: 35900112
No abstract available.
3.
Kitamura K, Okamoto A, Morio H, Isogai R, Ito R, Yamaura Y, et al.
Mol Pharm
. 2022 Jun;
19(8):2754-2764.
PMID: 35766901
Blood-brain barrier (BBB)-permeable middle- or macromolecules (middle/macromolecules) have recently attracted significant attention as new drug delivery carriers into the human brain via receptor-mediated transcytosis (RMT). During the development process of...
4.
Asaumi R, Nunoya K, Yamaura Y, Taskar K, Sugiyama Y
CPT Pharmacometrics Syst Pharmacol
. 2022 May;
11(7):919-933.
PMID: 35570332
P-glycoprotein (P-gp) is an efflux transporter that plays an important role in the pharmacokinetics of its substrate, and P-gp activities can be altered by induction and inhibition effects of rifampicin....
5.
Mochizuki T, Aoki Y, Yoshikado T, Yoshida K, Lai Y, Hirabayashi H, et al.
Clin Transl Sci
. 2022 Apr;
15(6):1519-1531.
PMID: 35421902
The accurate prediction of OATP1B-mediated drug-drug interactions (DDIs) is challenging for drug development. Here, we report a physiologically-based pharmacokinetic (PBPK) model analysis for clinical DDI data generated in heathy subjects...
6.
Mochizuki T, Zamek-Gliszczynski M, Yoshida K, Mao J, Taskar K, Hirabayashi H, et al.
Clin Pharmacol Ther
. 2022 Mar;
111(6):1315-1323.
PMID: 35292967
This study was designed to assess the quantitative performance of endogenous biomarkers for organic anion transporting polypeptide (OATP) 1B1/1B3-mediated drug-drug interactions (DDIs). Ten healthy volunteers orally received OATP1B1/1B3 probe cocktail...
7.
Ito R, Morio H, Baba T, Sakaguchi Y, Wakayama N, Isogai R, et al.
Pharm Res
. 2022 Mar;
39(7):1575-1586.
PMID: 35288803
Purpose: In vitro human blood-brain barrier (BBB) models in combination with central nervous system-physiologically based pharmacokinetic (CNS-PBPK) modeling, hereafter referred to as the "BBB/PBPK" method, are expected to contribute to...
8.
Kono K, Fujimura R, Nakamura Y, Matsuura K, Nunoya K, Yamaura Y, et al.
Mol Pharm
. 2022 Feb;
19(3):798-804.
PMID: 35179021
In human plasma, the main agent of hydrolysis of the ester-type prodrug of levodopa, designated ONO-2160, is alpha-1-acid glycoprotein (AGP), which is a mixture of the F1*S and A variants...
9.
Kitamura K, Umehara K, Ito R, Yamaura Y, Komori T, Morio H, et al.
Biol Pharm Bull
. 2021 Apr;
44(7):984-991.
PMID: 33896887
In vitro blood-brain barrier (BBB) models are essential research tools for use in developing brain-targeted drugs and understanding the physiological and pathophysiological functions of the BBB. To develop BBB models...
10.
Kono K, Nunoya K, Nakamura Y, Bi J, Mukunoki A, Takeo T, et al.
Mol Pharm
. 2021 Apr;
18(5):1985-1991.
PMID: 33861617
Previously, we found that ONO-2160, an ester-type prodrug of levodopa (3-hydroxy-l-tyrosine), was mainly hydrolyzed in human plasma by α-acid glycoprotein (AGP) with a partial contribution of albumin. In this study,...